High-validity RWE company welcomes Cheifetz
and Melmed
PALO
ALTO, Calif., Aug. 1, 2024
/PRNewswire/ -- Verantos, the global leader in high-validity
real-world evidence at scale, today announced that Adam S. Cheifetz, M.D. of Beth Israel
Deaconess Medical Center, and Gil Y.
Melmed, M.D. of Cedars-Sinai Medicine, have joined its
advisory panel for inflammatory bowel disease (IBD). As senior
faculty and experts, they will provide expert input on
observational research powered by Verantos' Inflammatory Bowel
Disease Pragmatic Registry.
"These global experts in inflammatory bowel disease will provide
critical insights into the interplay between real-world data and
clinical care," said Verantos CEO Dan
Riskin. "We are proud to welcome Drs. Cheifetz and Melmed as
we continue to enhance our industry-leading Inflammatory Bowel
Disease Pragmatic Registry."
Dr. Cheifetz is Director of the Center for Inflammatory Bowel
Disease and Medical Director of Infusion Services at Beth Israel
Deaconess Medical Center, and a practicing gastroenterologist.
Cheifetz specializes in the treatment of inflammatory bowel
diseases, is involved in multiple IBD research projects, and has
published over 250 articles and chapters on IBD. His current
research includes therapeutic drug monitoring and optimizing the
use of biologics through the proactive use of drug
concentrations.
Dr. Melmed is Director of inflammatory bowel disease clinical
research at the Inflammatory Bowel Disease Institute, Associate
Division Director of the Karsh Division of Gastroenterology and
Hepatology, and a practicing gastroenterologist at Cedars-Sinai.
Melmed's research includes improving quality of care for patients
with IBD and improving IBD clinical and surgical outcomes. He also
oversees clinical trials of novel agents for Crohn's disease and
ulcerative colitis.
Verantos Pragmatic Registries are disease-specific registries
generated from routinely collected, real-world data. Life sciences
companies can subscribe to these rich and reliable data sets to
enable high-validity real-world evidence.
About Drs. Cheifetz and Melmed
Dr. Adam Cheifetz is Professor of Medicine at
Harvard Medical School. He is a
well-recognized leader in the treatment of Crohn's disease,
ulcerative colitis, and other inflammatory bowel diseases. Dr.
Cheifetz was the first to demonstrate that proactive monitoring of
infliximab and adalimumab concentrations and dosing to a
therapeutic window improves outcomes compared to standard care.
Dr. Gil Melmed is Professor of
Medicine at Cedars-Sinai. He has authored or co-authored more than
200 articles in peer-reviewed journals and several book chapters
and has lectured nationally and internationally on IBD-related
topics. He is a current or past committee member of several
professional organizations, including the American Gastroenterology
Association (AGA), the American College of Gastroenterology, and
the Crohn's & Colitis Foundation of America (CCFA), where he
serves as co-chair of the IBD Quality of Care committee. He has led
or participated in developing quality indicators for IBD with the
AGA, CCFA, the National Quality Forum, and the Canadian Crohn's and
Colitis organizations.
About Verantos
Verantos is the global leader in
high-validity real-world evidence at scale. By applying artificial
intelligence to the complete patient record, Verantos enables life
sciences organizations to generate high-validity evidence across
therapeutic areas with measured accuracy, completeness, and
traceability. Credible evidence accelerates clinical development,
market access, medical affairs, pharmacovigilance, and regulatory
initiatives.
Media Contact
Smriti Shakargaye for Verantos
prforverantos@bospar.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/distinguished-experts-join-verantos-inflammatory-bowel-disease-advisory-panel-302212485.html
SOURCE Verantos